OSE2101 for Non-Small Cell Lung Cancer with Resistance to Immunotherapy
This study is testing a therapeutic cancer vaccine called OSE2101 in people with non-small cell lung cancer (NSCLC) that has stopped responding to previous immunotherapy. OSE2101 is a vaccine designed to help your immune system recognize and fight cancer cells. It targets specific proteins found on cancer cells. The study will compare OSE2101 to docetaxel, a standard chemotherapy drug. To join, you must be at least 18 years old, have the HLA-A2 genetic marker (a specific immune system type), and have NSCLC that has spread and is not treatable with surgery or radiation. The main goal is to see if OSE2101 can help people live longer. Researchers will also look for specific biomarkers (like ALK, BRAF, EGFR, KRAS, ROS1) to understand how the treatments work.
- Study design
- This is a phase 3 study that will include 363 participants. It is randomized, meaning you will be assigned by chance to receive either OSE2101 or docetaxel.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your overall survival will be tracked from the time you are assigned to a treatment group until death, for an average of 3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
At a glance
Conditions
Where it's being run
207 sites across 92 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- OS defined as time from randomization to deathFrom randomization date through study completion, an average of 3 years
OS defined as time from randomization to death of any cause, censored until the data analysis cut-off date